Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024)
Rhythm Pharmaceuticals (RYTM) posted quarterly Non-Current Deffered Revenue of $109.2 million for Q3 2024, up 4.34% year-over-year from $104.7 million in Q4 2023, and up 0.8% quarter-over-quarter from $108.4 million in Q2 2024.
Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Non-Current Deffered Revenue for 8 consecutive years, with $109.2 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Non-Current Deffered Revenue rose 4.34% year-over-year to $109.2 million; the TTM figure through Sep 2024 stood at $109.2 million (up 4.34% YoY), while the FY2023 annual figure was $106.1 million, up 40.01% from the prior year.
- Non-Current Deffered Revenue climbed to $109.2 million in Q3 2024 per RYTM's latest filing, from $108.4 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $109.2 million in Q3 2024 and bottomed at $3.0 million in Q1 2020.
- Historically, Non-Current Deffered Revenue has averaged $85.7 million across 4 years, with a median of $104.7 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue surged 40.01% — and 2024, when it rose 4.34%.
- Rhythm Pharmaceuticals' Non-Current Deffered Revenue stood at $3.0 million in 2020, then jumped by 2462.01% to $75.8 million in 2022, then soared by 40.01% to $106.1 million in 2023, then increased by 2.92% to $109.2 million in 2024.
- Business Quant data shows RYTM's Non-Current Deffered Revenue at $109.2 million in Q3 2024, $108.4 million in Q2 2024, and $107.4 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 109.24 Mn |
| Jun 30, 2024 | 108.37 Mn |
| Mar 31, 2024 | 107.37 Mn |
| Dec 31, 2023 | 106.14 Mn |
| Sep 30, 2023 | 104.70 Mn |
| Jun 30, 2023 | 79.35 Mn |
| Mar 31, 2023 | 77.52 Mn |
| Dec 31, 2022 | 75.81 Mn |
| Mar 31, 2020 | 2.96 Mn |
| Dec 31, 2019 | 3.09 Mn |
| Dec 31, 2018 | 372,000.00 |
| Sep 30, 2018 | 288,000.00 |
| Jun 30, 2018 | 185,000.00 |
| Mar 31, 2018 | 206,000.00 |
| Dec 31, 2017 | 228,000.00 |
| Sep 30, 2017 | 250,000.00 |
| Dec 31, 2016 | 311,000.00 |